Equities Analysts Set Expectations for NRSN FY2025 Earnings

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) – Equities researchers at Noble Financial lifted their FY2025 earnings estimates for NeuroSense Therapeutics in a research report issued on Thursday, February 19th. Noble Financial analyst R. Leboyer now expects that the company will post earnings of ($0.37) per share for the year, up from their prior estimate of ($0.40).

NRSN has been the topic of a number of other research reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research report on Monday, December 29th. Wall Street Zen upgraded NeuroSense Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, January 3rd. Finally, D. Boral Capital reissued a “buy” rating and issued a $14.00 price target on shares of NeuroSense Therapeutics in a report on Monday, December 22nd. One analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

NeuroSense Therapeutics Price Performance

NRSN stock opened at $0.90 on Monday. NeuroSense Therapeutics has a 52-week low of $0.68 and a 52-week high of $2.60. The company’s 50-day simple moving average is $0.91 and its 200-day simple moving average is $1.06.

Institutional Investors Weigh In On NeuroSense Therapeutics

A number of hedge funds have recently modified their holdings of the business. Two Sigma Investments LP acquired a new position in NeuroSense Therapeutics during the third quarter worth about $26,000. Jane Street Group LLC acquired a new position in shares of NeuroSense Therapeutics during the 2nd quarter worth approximately $54,000. Yorkville Advisors Global LP purchased a new stake in shares of NeuroSense Therapeutics in the fourth quarter valued at approximately $77,000. Finally, Squarepoint Ops LLC increased its holdings in shares of NeuroSense Therapeutics by 91.0% in the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock valued at $119,000 after purchasing an additional 45,450 shares during the last quarter. 1.04% of the stock is currently owned by institutional investors and hedge funds.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.